Key points are not available for this paper at this time.
The prevalence of AMD is anticipated to increase worldwide to 288 million individuals by 2040. Intravitreally administered anti-VEGF treatment is first-line therapy for exudative neovascular AMD.
Fleckenstein et al. (Tue,) studied this question.